Pages that link to "Q63641262"
Jump to navigation
Jump to search
The following pages link to Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes (Q63641262):
Displaying 50 items.
- Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine (Q24597369) (← links)
- Multiple sclerosis: the role of cytokines in pathogenesis and in therapies (Q27011014) (← links)
- Smoking-related interstitial lung disease (Q27027779) (← links)
- No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine (Q28268596) (← links)
- Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c (Q28368340) (← links)
- Development of oral immunomodulatory agents in the management of multiple sclerosis (Q28388704) (← links)
- Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells (Q28548449) (← links)
- Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases (Q28620349) (← links)
- Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study (Q33363695) (← links)
- Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation? (Q33390319) (← links)
- 2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies (Q33492144) (← links)
- A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma (Q33639281) (← links)
- Promising treatments of tomorrow for multiple sclerosis (Q33670947) (← links)
- Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues (Q33721126) (← links)
- Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis (Q33802186) (← links)
- Cladribine tablets: in relapsing-remitting multiple sclerosis (Q33821160) (← links)
- Interleukin-6 functions as an intracellular growth factor in hairy cell leukemia in vitro (Q33907983) (← links)
- Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies (Q33991278) (← links)
- Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study (Q34053766) (← links)
- Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets (Q34133316) (← links)
- Toxicities of immunosuppressive treatment of autoimmune neurologic diseases (Q34257903) (← links)
- Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy (Q34263013) (← links)
- Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies (Q34290943) (← links)
- Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice (Q34441015) (← links)
- Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes (Q34529077) (← links)
- Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs (Q34547269) (← links)
- Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents (Q34714866) (← links)
- Development of oral cladribine for the treatment of multiple sclerosis (Q35013390) (← links)
- Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis (Q35606563) (← links)
- Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators (Q35691048) (← links)
- Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions (Q35766988) (← links)
- Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine (Q36267473) (← links)
- Pharmacokinetic optimisation of anticancer therapy (Q36890315) (← links)
- Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (Q36931065) (← links)
- Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. (Q37424784) (← links)
- The treatment of chronic progressive multiple sclerosis with cladribine (Q37725229) (← links)
- Managing MS in a changing treatment landscape. (Q37857752) (← links)
- The combination effects of bendamustine with antimetabolites against childhood acute lymphoblastic leukemia cells (Q38793446) (← links)
- Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors (Q39246291) (← links)
- Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells (Q40393276) (← links)
- Potential Immunological Action of Purine Nucleoside Analogues (Q40394311) (← links)
- New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase (Q40643843) (← links)
- The clinical pharmacokinetics of cladribine (Q41382502) (← links)
- Modulation of apoptosis by adenosine in the central nervous system: a possible role for the A3 receptor. Pathophysiological significance and therapeutic implications for neurodegenerative disorders (Q41643072) (← links)
- Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells (Q42216636) (← links)
- 2 chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms (Q42390436) (← links)
- Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia (Q42660093) (← links)
- 2-Chloro-2'-deoxyadenosine monophosphate residues in DNA enhance susceptibility to 3'-->5' exonucleases (Q42829076) (← links)
- Cladribin. Development of an oral formulation for the treatment of multiple sclerosis (Q43176404) (← links)
- Hematological effects of intermittent 2-hour infusions of cladribine in multiple sclerosis patients: a comparison of 2 dosage patterns. (Q43856820) (← links)